Thank you, Josh. We're very proud of the results again this quarter for both revenue and adjusted EBITDA. We had 34% top line growth on top of 34% growth in Q1 last year, supported by our cloud and services revenue, which grew 51.5% year-over-year. This came from growth in both users and premium product add-ons driving upsell. Demand for TASER 10 also remained robust and drove 33% growth year-over-year in our TASER segment, supported by increasing supply availability. Sensors and other revenue grew 14% year-over-year with the adoption of Axon Body 4 driving camera revenue, somewhat offset by lapping the big catch-up in fleet revenue from Q1 last year as we're now at more normalized deployment levels. In addition to healthy growth across all our categories, we see strength across our end markets. In Q1, over 25% of our revenue came from outside domestic law enforcement, including international, federal, other adjacent markets like corrections in Justice and Enterprise. Our ARR for the quarter is $825 million, up almost 50% year-over-year, and it now includes Fusus and our TASER warranty revenue. We continue to maintain a net revenue retention of 122%. In Q1, we introduced adjusted gross margin to normalize for increased stock-based compensation resulting from the grants we made to employees whose compensation was under a specified threshold, many of whom are in manufacturing. As a reminder, we've committed to keeping our stock-based compensation at or below an average annual dilution of 3% for 2025 and beyond, and this is in keeping with that commitment. Adjusted gross margin for the quarter was 63.2%, up from 61.5% in Q4. This improvement was from product mix benefit as well as the fact we didn't have any onetime reserves hit this quarter. We do expect some pressure on gross margin for the rest of the year as we continue to balance mix shift and ramping T10 capacity. Q1 adjusted EBITDA margin increased year-over-year from 19% to 23.6%, representing a 460 basis point improvement. In addition to the benefit of strong gross margins, we saw operating leverage contribute approximately 110 basis points year-over-year. As Josh mentioned, this is our strongest adjusted EBITDA margin quarter in 3 years since COVID. We continue to balance driving strong top line growth with investing in the business. We're pleased to be able to do this both organically and inorganically and are thrilled about our plans to welcome the Dedrone team to Axon. Rick did a great job talking through the strategic rationale. From a financial standpoint, we expect to close the deal sometime over the summer and to have approximately one full quarter of financials included in our 2024 results. This timing is subject to customary closing conditions. We expect that the potential acquisition of Dedrone would increase our TAM by $14 billion, bringing our overall addressable market to $77 billion. Dedrone is still investing for growth, and we expect incremental costs from their business and from integration that would have a slight impact to our core adjusted EBITDA margin. We've tried to factor this into our updated guidance and should be able to further refine these assumptions next quarter. Today, Dedrone is small relative to our overall business, and once closed, you will see them incorporated into our Software and Sensors segment. Dedrone highlights another step in our M&A strategy of acquiring talent and technology that complements our road map and expands our addressable market. In total, our acquisitions of Sky-Hero and Fusus and our planned acquisition of Dedrone have expanded our TAM by more than 50% over the last year from $50 billion to $77 billion. The acquisitions also increased our capabilities in robotic security and real-time operations, both areas we view as critical to the future of policing and our other markets, and we are excited to continue delivering on our product vision. Finally, I'll turn to our guidance. We are increasing our full year 2024 expected revenue guidance to $1.94 billion to $1.99 billion, which represents approximately 26% annual growth at the midpoint, above the prior high end of our guidance range of 20% to 24%. This incorporates both our outperformance in Q1 and our increased expectations for the year. While future contracted revenue was down slightly quarter-over-quarter to $7 billion in Q1, we have a strong pipeline for the year to underpin our forecast. We have also included an immaterial amount of revenue we expect to come from Dedrone this year, reflecting everything we currently know. We expect adjusted EBITDA of $430 million to $445 million, which implies an adjusted EBITDA margin of approximately 22% up year-over-year and approximately in line with our prior guidance on margin. This includes our best estimate of integration costs and impact from M&A on the year. Finally, we've also increased our expected investment in CapEx to $80 million to $95 million for the year as we are continuing to ramp our capacity investments to meet the strong demand for TASER 10. We're very pleased with these results and think the quarter demonstrates continued execution on our business across both the top and bottom line as well as strong investments for the future so we can continue to deliver outsized performance. And with that, I would like to open it up to questions.